On August 6, LEADS BIOLABS-B rose 5.34% in regular trading, trading at HK$60.9/share, with turnover of HK$75.61 million. The gain was driven by the company's announcement that its PD-L1/4-1BB bispecific antibody Opamtistomig has successfully completed the safety run-in period evaluation and entered the expansion stage of its Phase II clinical study for first-line treatment of hepatocellular carcinoma (HCC).

According to the company's disclosure, the expansion milestone was reached following expert review of safety data. HCC is characterized by insidious onset, with fewer than 30% of patients eligible for curative treatment at initial diagnosis, underscoring the critical role of systemic anti-tumor therapy for intermediate-to-advanced cases. This progress follows a series of positive developments for the company's core pipeline, including IND approval for metastatic colorectal cancer granted on August 3, priority review designation for extrapulmonary neuroendocrine carcinoma in July, and six research results selected for presentation at ESMO 2026, including two highest-tier oral presentations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)